Kweichow Moutai Presents Chinese Enterprise’s ESG Insights at 2025 WEF
24.1.2025 17:49:00 EET | Business Wire | Press release
Wang Li, General Manager of Kweichow Moutai Group, China's top liquor company, was invited to participate in the 2025 World Economic Forum (WEF) Annual Meeting, which officially opened recently, and shared the Moutai solutions on topics such as ESG practices, green and low-carbon development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124612942/en/
Wang Li, General Manager of Kweichow Moutai Group, presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon. (Photo: Business Wire)
At the 2025 Davos-Tencent Finance Vision Dinner, Wang explained the ESG development based on Moutai's practices. She said that Moutai adheres to long-termism and high-quality development, integrates the ESG concept into the entire production and operation process. By pursuing sustainable development from three dimensions: harmonious coexistence with nature, sharing of social value, and modernization of self-governance, Moutai accumulates momentum and advantages for future development.
Besides, Wang Li presented Moutai's advanced experience in green technological innovation at the Davos-Caixin CEO luncheon as well. She said that Moutai liquor is the result of adhering to harmonious coexistence between mankind and nature. Kweichow Moutai Group insists on leveraging the innovative power of green technology to support the company's green development, focusing on "energy saving, carbon reduction, emission reduction, and efficiency improvement" to achieve "greening level improvement of the main value chain".
Through the resource utilization, greening and high-end development of the by-products in the liquor industry, Moutai has realized the utilization of its by-products. Looking to the future, Moutai will be committed to applying more innovative power and methods of green technology to maintain the characteristics of its products.
Furthermore, Wang proposed Moutai's carbon reduction solution at the First Movers Coalition Leadership Meeting. Wang said, “The accurate management of the whole chain is an important feature of Moutai's carbon emission management. Moutai accounts for the carbon footprint of the whole life cycle of its products and has formulated targeted programs for the transformation of the energy structure, the reduction and greening of packaging materials, etc.”
Moutai also pays attention to the recycling of post-drinking packages, and plans to start post-drinking package recycling in China's provincial capitals in 2025, with the goal of reducing the carbon emissions of the whole industrial chain by 20% by 2030.
During the WEF, Wang Li will also take part in the “China Night” dialogue, sharing Moutai's wisdom with Chinese and foreign experts on the thinking of Chinese enterprises in coping with the age of intelligence and the shaping of the international image of Chinese enterprises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124612942/en/
Contacts
Eason Zhou
Email: evisionsinfo@gmail.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom